Test Code HI/MOD Risk Common Cancer Managment Panel
Performing Laboratory
BioReference- GeneDx
Methodology
- Deletion/Duplication Analysis
- Next-Gen Sequencing
- MLPA
Reference Values
See Report
Includes Genes:
APC, ATM, AXIN2, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL
Physician Office Specimen Requirements
Container/Tube: Lavender top tube
Specimen: 2 - 5 mL whole blood
Transport Temperature: Room Temperature
Computer Interface Code
PDM # 1659844
Useful For
- The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple cases of ovarian cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM). Thus, the OncoGeneDx High/Moderate Risk Panel offers increased clinical sensitivity compared to testing only for the BRCA genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering BRCA testing followed by additional genetic testing).
- The family history includes a number of cancer cases, but they are of several different types. Therefore, the pattern does not seem to fit any one hereditary cancer syndrome in particular.
- Some genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition, and results have been negative. OncoGeneDx High/Moderate Risk Panel includes three recently described, but well-studied, cancer predisposition genes (ATM, CHEK2, PALB2) in addition to genes associated with classic hereditary cancer syndromes, and may allow for detection of a causative mutation after initial testing is uninformative
CPT Coding
81162
81201
81292
81295
81307
TAT; 14 Days